Tessa Therapeutics Appoints David McIntyre as Chief Financial Officer BEDMINSTER, N.J. and SINGAPORE, Dec. 17, 2020 /PRNewswire/ -- Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments, today announced the appointment of David McIntyre as its Chief Financial Officer. Mr. McIntyre brings over 25 years of global financial, operational and legal experience, including over 10 years as Chief Financial Officer of various publicly listed and privately held entities. He joins Tessa from AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), where he served as the Chief Financial Officer. Before joining AVITA Medical, Mr. McIntyre served as a Partner with Apple Tree Partners (ATP), a multibillion-dollar life science venture capital and growth equity fund. At ATP Mr. McIntyre was responsible for ATP's medical device portfolio, together with various operating and Board functions, including acting as CFO and Head of Technical Operations at Braeburn, Inc.